Cancers, Vol. 16, Pages 1378: Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study

Cancers, Vol. 16, Pages 1378: Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study Cancers doi: 10.3390/cancers16071378 Authors: Matheus Sewastjanow-Silva Lianchun Xiao Graciela N. Gonzalez Xuemei Wang Wayne Hofstetter Stephen Swisher Reza Mehran Boris Sepesi Manoop S. Bhutani Brian Weston Emmanuel Coronel Rebecca E. Waters Jane E. Rogers Jackie Smith Larry Lyons Norelle Reilly James C. Yao Jaffer A. Ajani Mariela Blum Murphy Efforts to improve the prognosis for patients with locally advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma have focused on neoadjuvant approaches to increase the pathological complete response (pathCR) rate, improve surgical resection, and prolong event-free and overall survival (OS). Building on the recent evidence that PD-1 inhibition plus chemotherapy improves the OS of patients with metastatic GEJ adenocarcinoma, we evaluated whether the application of this strategy in the neoadjuvant setting would improve the pathological response. This single-center phase I/II trial evaluated the safety, toxicity, and efficacy of neoadjuvant atezolizumab with oxaliplatin and 5-fluorouracil (modified FOLFOX) followed by esophagectomy followed by atezolizumab. The primary objective goal was to achieve 20% pathCR. From the twenty enrolled patients, eighteen underwent resection and two (10%, 95% CI: 1.24...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research